Efficacy of Kolofort in Combined Functional Gastroenterological Pathology: an Open Study
Aim. The study aims to evaluate the efficacy and safety of Kolofort administration in patients suffering from irritable bowel syndrome (IBS) and functional dyspepsia (FD), as well as the prevalence of somatic and polymorbid psychomental disorders (distress, depression, anxiety and somatisation) in t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2020-12-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/529 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860150294806528 |
|---|---|
| author | Yu. P. Uspenskiy O. S. Mirzoev Yu. A. Fominykh A. A. Gnutov S. V. Polyushkin |
| author_facet | Yu. P. Uspenskiy O. S. Mirzoev Yu. A. Fominykh A. A. Gnutov S. V. Polyushkin |
| author_sort | Yu. P. Uspenskiy |
| collection | DOAJ |
| description | Aim. The study aims to evaluate the efficacy and safety of Kolofort administration in patients suffering from irritable bowel syndrome (IBS) and functional dyspepsia (FD), as well as the prevalence of somatic and polymorbid psychomental disorders (distress, depression, anxiety and somatisation) in these patient groups using questionnaires “7×7” and “4DSQ”.Materials and methods. The study included 56 patients with IBS and FD diagnosed according to the Rome IV revision criteria and the Clinical Guidelines of the Russian Gastroenterological Association, the average age was 36.36 ± 6.42 years. All patients received Kolofort 2 times a day, 2 tablets per dose for 28 days.Results. The Kolofort therapy improved the clinical symptoms according to the “7x7” questionnaire; the primary mean total score was 17.7 ± 3.6, decreased to 10.3 ± 2.5 past 14 days (p < 0.0001) and to 7.6 ± 1.5 - past 28 days of therapy (p < 0.0001). On the 28th day of therapy, a 4DSQ survey revealed a 49.9% growth in patients with absent distress, a 29.3% decrease in moderate and 20.6% — in high distress cases (p < 0.0001). On the same term, the number of patients without depression increased by 21.4%, decreased by 17.9% with moderate depression and by 3.4% - with severe depression (p = 0.003); the number of patients without anxiety increased by 32.0%, decreased by 8.9% with moderate and by 23.1% — with severe anxiety (p < 0.0001); the number of patients with absent somatisation increased by 53.9%, decreased by 37.1% with moderate and by 18.6% — with severe somatisation (p < 0.0001).Conclusion. Patients with combined IBS and FD exhibit a high prevalence and severity of both somatic and polymorbid mental symptoms. The Kolofort therapy effectively suppresses clinical symptoms and reduces distress, depression, anxiety and somatisation. |
| format | Article |
| id | doaj-art-a3ae9ad593354977b06ebc92488aabec |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2020-12-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-a3ae9ad593354977b06ebc92488aabec2025-02-10T16:14:36ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732020-12-01305304110.22416/1382-4376-2020-30-5-30-41394Efficacy of Kolofort in Combined Functional Gastroenterological Pathology: an Open StudyYu. P. Uspenskiy0O. S. Mirzoev1Yu. A. Fominykh2A. A. Gnutov3S. V. Polyushkin4Saint-Petersburg State Pediatric Medical University; Pavlov First Saint-Petersburg State Medical UniversitySaint-Petersburg State Pediatric Medical UniversityPavlov First Saint-Petersburg State Medical UniversitySaint-Petersburg State Pediatric Medical UniversitySaint-Petersburg State Pediatric Medical University; Rehabilitation Centre of the Russian President AdministrationAim. The study aims to evaluate the efficacy and safety of Kolofort administration in patients suffering from irritable bowel syndrome (IBS) and functional dyspepsia (FD), as well as the prevalence of somatic and polymorbid psychomental disorders (distress, depression, anxiety and somatisation) in these patient groups using questionnaires “7×7” and “4DSQ”.Materials and methods. The study included 56 patients with IBS and FD diagnosed according to the Rome IV revision criteria and the Clinical Guidelines of the Russian Gastroenterological Association, the average age was 36.36 ± 6.42 years. All patients received Kolofort 2 times a day, 2 tablets per dose for 28 days.Results. The Kolofort therapy improved the clinical symptoms according to the “7x7” questionnaire; the primary mean total score was 17.7 ± 3.6, decreased to 10.3 ± 2.5 past 14 days (p < 0.0001) and to 7.6 ± 1.5 - past 28 days of therapy (p < 0.0001). On the 28th day of therapy, a 4DSQ survey revealed a 49.9% growth in patients with absent distress, a 29.3% decrease in moderate and 20.6% — in high distress cases (p < 0.0001). On the same term, the number of patients without depression increased by 21.4%, decreased by 17.9% with moderate depression and by 3.4% - with severe depression (p = 0.003); the number of patients without anxiety increased by 32.0%, decreased by 8.9% with moderate and by 23.1% — with severe anxiety (p < 0.0001); the number of patients with absent somatisation increased by 53.9%, decreased by 37.1% with moderate and by 18.6% — with severe somatisation (p < 0.0001).Conclusion. Patients with combined IBS and FD exhibit a high prevalence and severity of both somatic and polymorbid mental symptoms. The Kolofort therapy effectively suppresses clinical symptoms and reduces distress, depression, anxiety and somatisation.https://www.gastro-j.ru/jour/article/view/529combined functional digestive disordersfunctional dyspepsiairritable bowel syndromedistressdepressionanxietysomatisation“7x7” questionnaire4dsqkolofort |
| spellingShingle | Yu. P. Uspenskiy O. S. Mirzoev Yu. A. Fominykh A. A. Gnutov S. V. Polyushkin Efficacy of Kolofort in Combined Functional Gastroenterological Pathology: an Open Study Российский журнал гастроэнтерологии, гепатологии, колопроктологии combined functional digestive disorders functional dyspepsia irritable bowel syndrome distress depression anxiety somatisation “7x7” questionnaire 4dsq kolofort |
| title | Efficacy of Kolofort in Combined Functional Gastroenterological Pathology: an Open Study |
| title_full | Efficacy of Kolofort in Combined Functional Gastroenterological Pathology: an Open Study |
| title_fullStr | Efficacy of Kolofort in Combined Functional Gastroenterological Pathology: an Open Study |
| title_full_unstemmed | Efficacy of Kolofort in Combined Functional Gastroenterological Pathology: an Open Study |
| title_short | Efficacy of Kolofort in Combined Functional Gastroenterological Pathology: an Open Study |
| title_sort | efficacy of kolofort in combined functional gastroenterological pathology an open study |
| topic | combined functional digestive disorders functional dyspepsia irritable bowel syndrome distress depression anxiety somatisation “7x7” questionnaire 4dsq kolofort |
| url | https://www.gastro-j.ru/jour/article/view/529 |
| work_keys_str_mv | AT yupuspenskiy efficacyofkolofortincombinedfunctionalgastroenterologicalpathologyanopenstudy AT osmirzoev efficacyofkolofortincombinedfunctionalgastroenterologicalpathologyanopenstudy AT yuafominykh efficacyofkolofortincombinedfunctionalgastroenterologicalpathologyanopenstudy AT aagnutov efficacyofkolofortincombinedfunctionalgastroenterologicalpathologyanopenstudy AT svpolyushkin efficacyofkolofortincombinedfunctionalgastroenterologicalpathologyanopenstudy |